Amanote Research
Register
Sign In
Evidence for the Efficacy of Enzalutamide in Postchemotherapy Metastatic Castrate-Resistant Prostate Cancer
Therapeutic Advances in Urology
- United States
doi 10.1177/1756287213490054
Full Text
Open PDF
Abstract
Available in
full text
Categories
Urology
Date
June 11, 2013
Authors
Fred Saad
Publisher
SAGE Publications
Related search
Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
Clinical Medicine Insights: Oncology
Oncology
Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer
Urologic Clinics of North America
Urology
Heterogeneous Ensembles for Predicting Survival of Metastatic, Castrate-Resistant Prostate Cancer Patients
F1000Research
Genetics
Molecular Biology
Pharmacology
Biochemistry
Microbiology
Immunology
Medicine
Toxicology
Pharmaceutics
Guidelines for the Management of Castrate-Resistant Prostate Cancer
Journal of the Canadian Urological Association
Oncology
Urology
Guidelines for the Management of Castrate-Resistant Prostate Cancer
Canadian Urological Association Journal
Urology
Molecular Drivers of Metastatic Castrate-Resistant Prostate Cancer: New Roads to Resistance
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy
Klinicka Onkologie
Oncology
Early Evidence of Anti-Pd-1 Activity in Enzalutamide-Resistant Prostate Cancer
Oncotarget
Oncology
Pcn37 - Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental